From Pieces to Progress
Managing wounds appropriately with AQUACEL® Ag Advantage gives your patients the chance to heal wounds
Hard-to-heal wounds, such as venous leg ulcers (VLUs), are a major challenge to healthcare systems globally5
- Estimated prevalence of ~1.9 per 1000 population6,7
- Associated with reduced patient health-related quality of life and substantial economic burden8,9
Biofilm has long been implicated in hard-to-heal wounds10
- At least 78% of hard-to-heal wounds are estimated to have biofilm11
- Biofilm can protect microorganisms from antibiotics, antiseptics and host immunity10
AQUACEL® Ag Advantage is a gelling fiber dressing with antibiofilm properties4
- Indicated for moderate to highly exuding hard-to-heal and acute wounds with infection or an increased risk of infection12
- Contains BEC and EDTA which work synergistically with iconic silver to disrupt and destroy biofilm4
AQUACEL® Ag Advantage achieved superior complete wound closure vs DACC dressings.1
A Multinational Randomized Controlled Trial¹
AQUACEL® Ag Advantage dressings are antimicrobial primary dressings for use in acute and hard-to-heal wounds that are infected or at risk of infection with varying exudate levels. They are specifically designed to manage biofilm within the dressing through a unique formulation of Hydrofiber® and MORE THAN SILVER™ technologies.9,1
Powered by Hydrofiber™ and More Than Silver™ technologies⁴
AQUACEL® Ag Advantage outperforms other silver-dressings to disrupt and destroy biofilm bacteria.² ³ ⁴ ¹²
BEC*, a surfactant, reduces the surface tension to enhance the anti-biofilm performance of AQUACEL® Ag Advantage dressing.14,15,16
EDTA, A metal chelating agent, EDTA helps disrupt biofilm by removing metal ions that hold the EPS matrix together to expose microorganisms to the antimicrobial effects of the ionic silver.15,17,18,19
IONIC SILVER, A broad-spectrum antimicrobial contained in a safe and effective quantity (1.2%) ensures cell death of the exposed bacteria by damaging the DNA, denaturing proteins and enzymes, and interfering with protein synthesis.4,20,21
Developing MORE THAN SILVERTM technology involved researching a wide range of biofilm-disrupting agents and surfactants in combination with ionic silver.4
Not all claims are supported in all regulatory geographies.
1.Beraldo S. et al. Effectiveness of an enhanced silver-containing dressing in hard-to-heal venous leg ulcers: a randomised controlled trial. Journal of Wound Care, 2025.
2.Meredith K, et al. Assessment of the Antibiofilm Performance of Silver-Containing Wound Dressings: A Dual-Species Biofilm Model. Cureus. 2024;16(9):e70086.
3.Meredith et al. Assessment of Silver-Containing Gelling Fiber Dressings Against Antibiotic-Resistant Pathogens Using an in vitro Biofilm Model. Infect Drug Resist. 2023 Nov 2;16:7015-7019.
4.Bowler PG & Parsons D. Combatting wound biofilm and recalcitrance with a novel anti-biofilm Hydrofiber® wound dressing. Wound Medicine 14 (2016) 6–11.
5.Rice JB et al. Burden of diabetic foot ulcers for medicare and private insurers. Diabetes Care 2014;37(3):651–658.
6.Martinengo L et al. Prevalence of chronic wounds in the general population: systematic review and meta-analysis of observational studies. Ann Epidemiol 2019;29:8–15.
7.Sen CK. Human Wound and Its Burden: Updated 2020 Compendium of Estimates. Adv Wound Care (New Rochelle) 2021;10(5):281–292.
8.Olsson M et al. The humanistic and economic burden of chronic wounds: A systematic review. Wound Repair Regen 2019;27(1):114–125.
9.Chan B et al. Cost-of-illness studies in chronic ulcers: a systematic review. J Wound Care 2017;26(Suppl 4):S4–S14.
10.James GA et al. Biofilms in chronic wounds. Wound Repair Regen 2008;16(1):37–44.
11.Malone M et al. The prevalence of biofilms in chronic wounds: a systematic review and meta-analysis of published data. J Wound Care 2017;26(1):20–25.
12.1708881v1 Instruction for Use, Convatec.
13.WC-22-435 clinical study report, Convatec 2024.
14.Parsons. Composition comprising antimicrobial metal ions and a quaternary cationic surfactant. WO2012136968A1.
15.Murphy et al. International consensus document. Embedding Wound Hygiene into a proactive wound healing strategy. J Wound Care 2022;31:S1–S24.
16.Hall-Stoodley L I et al. Towards diagnostic guidelines for biofilm-associated infections. FEMS Immunol Med Microbiol. 2012; 65:127–145.
17.Wolcott RD et al. Biofilm maturity studies indicate sharp debridement opens a time dependent therapeutic window. J Wound Care. 2010 Aug;19(8):320-8.
18.Banin et al. Chelator-Induced Dispersal and Killing of Pseudomonas aeruginosa Cells in Biofilm. Appl. Environ. Microbiol 2006; 72: 2064-2069.
19.Finnegan & Percival. EDTA: an antimicrobial and antibiofilm agent for use in wound care. Adv Wound Care (New Rochelle) 2015; 4: 415–421.
20.Lansdown. Silver 1: Its antibacterial properties and mechanisms of action. J Wound Care 2002; 11: 125-130.
21.Lansdown. The role of silver. Eur Tissue Rep Soc 2002; 9: 108-111.
*BEC, benzethonium chloride
®/™ all the trademarks are the property of Convatec group companies. ©2025 Convatec Inc. AP-73302-GBL-ENG-v1